Table 2.

Melanoma patient and sample characteristics, and HLA-A*0201 melanoma-associated antigen pentamer data.

Patient ID^a	Age^b	Sample source	MT			WT
Patient ID^a	Age^b	Sample source	# CD3⁺ CD8⁺ Pentamer⁺ T cells	# Total CD3⁺ CD8⁺ T cells	% CD3⁺ CD8⁺ Pentamer⁺	# CD3⁺ CD8⁺ Pentamer⁺ T cells	# Total CD3⁺ CD8⁺ T cells	% CD3⁺ CD8⁺ Pentamer⁺
2	44.6	PBMC	0	22,579	0	1	31,860	0.003
3	36.4	PBMC	0	52,035	0	120	99,126	0.12
4	36.3	PBMC	52	49,817	0.10	84	47,397	0.18
5	55.5	PBMC	6	10,759	0.06	33	50,362	0.07
11	58.1	PBMC	9	61,178	0.01	23	143,131	0.02
11	58.1	TIL	3	107	2.8^*	22	68,611	0.03
13	69.6	PBMC	5	77,809	0.01	6	53,777	0.01
		TILN-1^c	6	1,452	0.41^*	4	100,677	0.004
		TILN-2^c	16	128,326	0.01	7	160,979	0.004
16	45.8	PBMC	25	236,129	0.01	19	256,400	0.01
16	45.8	TILN	991	65,601	1.51^*	87	267,569	0.03
17	81.3	TIL	12	229,553	0.01	8	140,029	0.01
19	60.5	PBMC	18	283,938	0.01	95	132,098	0.07
20	57.0	PBMC	14	44,282	0.03	0	18,673	0

Patient ID assigned internally and reflects chronological order of analyzed samples. All patients were male except patient 11. All patients had Stage IV metastatic melanoma except patients 16 and 20, who had Stage III metastatic melanoma.

Age at time of initial blood sample acquisition for all patients except Patient 17, which is the age at time of tumor resection.

Two anatomically distinct TILN obtained on the same date were analyzed.

PBMC, peripheral blood mononuclear cells; TILN, tumor-infiltrated lymph node; TIL, tumor infiltrating lymphocytes

p<0.001, pentamer⁺ frequency MT compared to WT